Finerenone

点击“蓝字”关注我们 编者按：糖尿病患者中约30%~40%会发生慢性肾脏病（CKD），进而导致终末期肾病，且心血管疾病及死亡风险显著增加[1]。近期发布的《中国糖尿病合并慢性肾脏病临床管理共识》指出，在微量白蛋白尿阶段[尿白蛋白肌酐比值（UACR）30~299 mg/g]尽早积极干预，尿白蛋白更易转阴，对于及时延缓肾脏和心脏病理进展、避免过早出现不良肾心事件至关重要[2]。新型非甾体类盐皮质激素受体拮抗剂（MRA）非奈利酮具有抗炎抗纤维化的直接心肾保护机制，为2型糖尿病（T2DM）合并CKD患者提供新的治疗手段，助力控制白蛋白尿并提供肾心保护。本期复旦大学附属中山医院李晓牧教授与大家分享一例糖尿病肾病患者早期、足剂量应用非奈利酮干预白蛋白尿的临床病例，并邀请复旦大学附属中山医院陆志强教授进行点评。 病例作者 李晓牧教授 点评专家 陆志强教授 病例基本信息 患者男性，61岁，主因“发现血糖升高10余天伴泡沫尿”于2023年3月17日就诊。 病史及体格检查 现病史 T2DM病史26年，既往口服“沙格列汀二甲双胍缓释片1片bid、吡格列酮30 mg qd、格列齐特缓释片60 mg qd”降糖。患者无明显不适，通过扫描式葡萄糖监测发现血糖控制不佳（餐后2h血糖10.0 mmol/L），并出现泡沫尿。 既往史 眼底出血7年，曾激光治疗2次。糖尿病性肾病，原发性高血压，高脂血症，糖尿病伴神经系统并发症，视网膜病变、周围神经病变。 体格检查 血压135/75 mmHg，身高168 cm，体重75 kg，体重指数（BMI）25.8 kg/m2。心肺腹未见明显阳性体征。双下肢无浮肿。无双足底至踝部对称性麻木、发冷，无疼痛；有排汗异常，伴乏力腰酸。 实验室检查 血糖 入院空腹血糖5.2 mmol/L，餐后2h血糖10.1 mmol/L，HbA1c 8.2%。 肾功能 血肌酐58 μmol/L，估算肾小球滤过率（eGFR）105 ml/min/1.73m2，UACR 193.9 mg/g。尿蛋白+。 血钾 4.2 mmol/L。 血脂 低密度脂蛋白胆固醇3.56 mmol/L，甘油三酯1.75 mmol/L，总胆固醇5.9 mmol/L。 临床诊断 主要诊断 2型糖尿病     糖尿病肾病     糖尿病视网膜病变     糖尿病周围神经病变     糖尿病伴神经系统并发症 次要诊断 原发性高血压 高脂血症 治疗思路及用药调整 结合患者个体情况，李晓牧主任梳理该病例特点如下： 01 老年男性，T2DM病史长达26年，体型偏胖，属超重人群； 02 出现多种糖尿病相关并发症，包括糖尿病肾病、糖尿病视网膜病变、糖尿病周围神经病变等； 03 血糖控制不达标，伴泡沫尿，检查发现微量白蛋白尿，肾功能尚在正常范围内； 03 合并原发性高血压，血压控制尚可；合并高脂血症，血脂控制不达标。 结合上述特点，考虑到该例患者糖尿病病程长，合并多种并发症，伴多种心血管危险因素，尽管目前糖尿病肾病处于微量白蛋白尿的早期阶段，但未来发生肾心不良结局的风险较高，应重视直接肾心保护，全面干预疾病多重危险因素，在加强对血糖、血压、血脂综合管理基础上，及早启动对蛋白尿的早期管理，力求尽可能延缓肾病进展，并进一步降低心血管事件风险。因此，李晓牧主任调整治疗方案如下： 01 血糖管理：对于糖尿病合并CKD患者，降糖方案中应优先考虑具有心肾获益证据的降糖药物SGLT2i和GLP-1RA，同时考虑到该患者应尽快实现血糖达标并兼顾体重控制，因此将降糖方案调整为口服二甲双胍1000 mg bid、达格列净10 mg qd、吡格列酮30 mg qd，每周皮下注射司美格鲁肽0.25 mg； 02 血压管理：口服奥美沙坦酯/氨氯地平1片qd； 03 血脂管理：依洛尤单抗140 mg，每2周皮下注射1次； 04 尿蛋白管理：住院期间起始加用非奈利酮10 mg qd，以进一步管理白蛋白尿，并降低远期肾心不良事件进展风险。起始非奈利酮治疗时，患者eGFR 105 ml/min/1.73m2，血清钾水平4.2 mmol/L，根据说明书及指南推荐可应用标准剂量20 mg qd起始，临床上从安全稳妥考虑，先采用半剂量10 mg qd起始。 非奈利酮治疗2.5个月随访（2023年6月2日）：血钾4.35 mmol/L，eGFR 100.5 ml/min/1.73m2，血肌酐61 μmol/L，均较前无明显变化；而微量白蛋白尿明显下降，UACR降至78.8 mg/g，将非奈利酮剂量调整为20 mg qd。复查血糖较前改善，HbA1c降至7.8%；血压亦较前改善（113/73 mmHg）。 非奈利酮治疗6个月随访（2023年9月11日）：血钾4.55 mmol/L，eGFR 101.2 ml/min/1.73m2，血肌酐59 μmol/L，仍较前无明显变化；微量白蛋白尿继续下降，UACR降至41.5 mg/g，继续维持非奈利酮标准剂量20 mg qd治疗。复查血糖HbA1c实现达标（6.8%）。 非奈利酮治疗9个月随访（2023年12月20日）：血钾4.6 mmol/L，较前有所增高，嘱患者注意饮食；eGFR 96.2 ml/min/1.73m2，血肌酐70.2 μmol/L，仍较前无明显变化；微量白蛋白尿继续下降，UACR降至正常水平（28.9 mg/g），继续维持非奈利酮标准剂量20 mg qd治疗。 非奈利酮治疗13个月随访（2024年4月14日）：血钾4.5 mmol/L，eGFR 102.2 ml/min/1.73m2，血肌酐61.1 μmol/L，基本保持稳定水平；UACR维持在正常水平（17.6 mg/g），继续维持非奈利酮标准剂量20 mg qd治疗。 患者在非奈利酮治疗前后的尿白蛋白变化情况如图1所示。可见，在启用非奈利酮治疗后，患者微量白蛋白尿快速改善，治疗不足3个月UACR降幅即达60%，治疗9个月UACR恢复至正常水平，并在随后的治疗中维持疗效。 图1. 起始非奈利酮治疗前后的尿白蛋白变化 在非奈利酮治疗期间，监测血钾有轻微升高趋势，但一直在正常水平内（图2）；血压控制在正常范围内；eGFR基本无明显变化。 图2. 起始非奈利酮治疗前后的血钾变化 专家点评 CKD是糖尿病最主要的微血管并发症之一，是引起终末期肾病的主要原因。最新横断面研究显示，我国32.5%的T2DM患者合并CKD，其中知晓率和筛查率仅26%和55.3%，且血糖、血脂等综合达标情况不佳，疾病规范化诊疗及综合管理方面亟待进一步提高[3]。第六次中国慢性病及危险因素监测结果显示，我国大多数CKD患者处于肾病早期阶段[4]，但通常就诊时间太晚，错失治疗良机。糖尿病肾病治疗强调早诊断和早干预。UACR是肾心损伤的早期标志物，UACR异常可早于eGFR下降，是糖尿病合并CKD疾病预后的重要评估指标，且相较eGFR灵敏度更高[2]。临床上对于长病程T2DM患者，一旦发现蛋白尿，意味着肾心不良结局风险显著增加，需尽早干预。具体到该病例，其糖尿病病程26年，糖尿病肾病处于微量白蛋白尿（UACR 193.9 mg/g）的早期阶段，CKD分期G1A2期，通过加强综合管理，重视直接肾心保护，可最大限度延缓甚至逆转蛋白尿进展，改善肾心预后。 2024年6月，中华医学会内分泌学分会发布《中国糖尿病合并慢性肾脏病临床管理共识》（以下简称“《共识》”），为广大临床医生提供糖尿病合并CKD临床管理指导原则[2]。《共识》强调蛋白尿管理是综合管理的重要组成部分，推荐遵循积极的“30-30”原则：（1）把握尿白蛋白逆转时间窗，UACR≥30 mg/g时积极启动干预；（2）管理目标为UACR降幅≥30%，糖尿病肾病患者可降至<30 mg/g[2]。该原则与最新国内外权威指南相一致[5-7]。从该病例的治疗来看，及时抓住了尿白蛋白的“黄金干预期”，并很好地践行“30-30”原则，治疗后白蛋白尿不断减少，UACR逐渐恢复至正常水平，这对于改善患者远期肾心结局具有重要意义。 在控制蛋白尿及肾心获益药物的选择上，《共识》指出：高血糖、高血压、炎症和纤维化等多种危险因素均参与糖尿病合并CKD的疾病进程，通过促进白蛋白尿的发生发展进一步加重肾心组织损伤及不良预后，控制蛋白尿的治疗方案应针对不同危险因素进行综合管理。推荐首选ACEI/ARB、SGLT2i、非奈利酮进行T2DM合并CKD伴蛋白尿患者的白蛋白尿控制以及肾心保护[2]。该病例对于蛋白尿的控制措施非常规范，在应用ARB/CCB固定复方制剂、达格列净基础上，及时起始非奈利酮治疗，后调整至足剂量并维持治疗半年后，收效显著，实现了白蛋白尿转阴（UACR<30 mg/g）。 糖尿病合并CKD的传统治疗方法主要通过降压和降糖治疗来干预血流动力学改变和代谢异常，但无法充分阻断盐皮质激素受体（MR）过度活化导致的炎症和纤维化，新型MRA非奈利酮可直接阻断MR过度活化，独立于降压和降糖治疗，发挥抗炎抗纤维化作用，直击疾病本质，实现肾心共护。该病例应用非奈利酮以半剂量10 mg qd起始，2.5个月后积极调整至标准剂量20 mg qd，并在随后治疗中一直维持足剂量治疗。治疗期间规范监测血钾、血压、肾功能等情况的变化，整个用药期间患者无明显相关不良反应，未发生高钾血症，血压控制平稳，也没有出现男性乳房发育/乳房疼痛或肿块等性激素副作用，安全性和耐受性良好。 总之，该糖尿病肾病患者在微量白蛋白尿阶段，积极给予规范化蛋白尿干预措施，在传统标准治疗基础上及时起始非奈利酮，并坚持足剂量维持治疗，白蛋白尿逐渐改善，最终UACR恢复至正常水平，提示其肾病进展得到及时控制，同时安全性良好，治疗效果满意。临床上一旦发现糖尿病患者出现微量白蛋白尿，应积极抓住黄金干预期，早干预、早获益。 专家简介 李晓牧 教授  复旦大学附属中山医院 教授，主任医师，博士生导师 复旦大学附属中山医院内分泌科副主任、内分泌肿瘤亚专科主任 上海市医学会糖尿病学分会副主任委员，中华医学会糖尿病学分会青年副主任委员 主持国家自然科学基金5项，国家重点研发计划子课题1项 以第一或通讯作者在NC、PNAS等杂志发表SCI论文20余篇 陆志强  教授 复旦大学附属中山医院 医学博士，复旦大学附属中山医院内分泌科主任医师，教授，博士研究生导师 中华医学会内分泌学会委员兼神经内分泌学组副组长、肾上腺学组委员 中国康复医学会糖尿病预防与康复专委会常委 上海市医学会内分泌学会委员兼性腺学组组长 上海市中西医结合学会糖尿病及其并发症专委会常委 白求恩精神研究会内分泌和糖尿病学分会副秘书长兼罕见病专委会副主任委员 参考文献 （上下滑动可查看） 1. Pavkov ME, et al. IDF Atlas Reports: Diabetes and chronic kidney failure. https://diabetesaltlas.org/atlas/diabetes-and-kidney-disease.  2. 中华医学会内分泌学分会, 中国内分泌代谢病专科联盟. 中华内分泌代谢杂志. 2024; 40(06): 455-461. 3. Zhu DL, et al. Diabetes. 2023; 72(Suppl 1): 1373-P. 4. Wang L, et al. JAMA Intern Med. 2023; 183(4): 298-310. 5. ADA. Diabetes Care. 2024; 47(Suppl. 1): S1-S321. 6. 中华医学会肾脏病学分会专家组. 中华肾脏病杂志. 2021; 37(3): 255-304. 7. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney Int. 2022; 102(5S): S1-S127. 声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。 最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！ （来源：《国际糖尿病》编辑部） 版权声明 版权属《国际糖尿病》所有。欢迎个人转发分享。其他任何媒体、网站未经授权，禁止转载。

Several leading classes of therapies are exploring diverse mechanisms of action to treat CHF, including SGLT2 inhibitors, cardiac myosin activators, myeloperoxidase inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, cell therapies, and more. This growing focus is expected to drive the chronic heart failure market forward. In summary, the existing blockbuster therapies such as Entresto, recently approved SGLT2 inhibitors, and Soluble guanylate cyclase (sGC) stimulators, along with emerging cell therapies, peptides, monoclonal antibodies, and small molecules, together have the potential to drive the existing market along with securing a significant market share upon introduction of new entrants to the CHF treatment landscape. LAS VEGAS, Jan. 22, 2025 /PRNewswire/ -- DelveInsight's Chronic Heart Failure Market Insights report includes a comprehensive understanding of current treatment practices, chronic heart failure emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Chronic Heart Failure Market Report According to DelveInsight's analysis, the market size for chronic heart failure was found to be approximately USD 5.5 billion in the US in 2023. Among the 7MM, the US contributed the largest market share of the total CHF market size and will continue to experience a steep rise in the market size throughout the forecast period. As per DelveInsight's estimate, the total diagnosed prevalent cases of CHF in the 7MM were approximately 20 million in 2023. Heart failure with preserved ejection fraction (HFpEF) contributed to most of the cases. Within class-specific diagnosed prevalence of Heart failure, NYHA class II and class III contribute the maximum. Established chronic heart failure companies with approved therapies in the market are Novartis, Otsuka, Boehringer Ingelheim/Eli Lilly, Bayer/Merck, Amgen/Servier, scPharmaceuticals, and Lexicon Pharmaceuticals/Viatris. In addition, Daiichi Sankyo and American Regent are targeting adult patients with heart failure who are iron deficient. Among all the approved therapies, Novartis and Otsuka's Entresto, approved since 2015 in the US, is still the leading therapy generating more than USD 4 billion in the 7MM in 2023. Among, Eli Lilly's Jardiance and AstraZeneca's Farxiga, both SGLT2 inhibitors, Farxiga is the leading prescribed SGLT2 inhibitor globally by volume Leading chronic heart failure companies developing emerging therapies, such as Cytokinetics, Bayer, Eli Lilly, BioCardia, Mesoblast, Tenax Therapeutics, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Intra-Cellular Therapies, Cardurion Pharmaceuticals, Rivus Pharmaceuticals, and others are developing novel chronic heart failure drugs that can be available in the chronic heart failure market in the coming years. The promising chronic heart failure therapies in the pipeline include Omecamtiv Mecarbil, KERENDIA (finerenone), Tirzepatide (LY3298176), CardiAMP Cell Therapy, Ziltivekimab (NN6018), REVASCOR (rexlemestrocel-L), Levosimendan (TNX-103), Semaglutide, Balcinrenone (AZD9977) + dapagliflozin, Mitiperstat (AZD4831), Vicadrostat (BI 690517) + Empagliflozin, Cimlanod (CXL-1427/BMS-986231), Lenrispodun (ITI - 214), CRD-740, HU6, and others. In October 2024, Viatris entered into an exclusive licensing agreement with Lexicon Pharmaceuticals for INPEFA (sotagliflozin) in all markets outside of the US and EU. In September 2024, Bayer presented the late-breaking data of Phase III FINE-HEART findings of KERENDIA (finerenone) during a Hot Line session at the European Society of Cardiology (ESC) Congress 2024. In May 2024, Eli Lilly and Company committed an additional USD 5.3 billion manufacturing investment in the company's newest Indiana site to boost API production for tirzepatide and pipeline medicines. AstraZeneca expects the data of the Phase III BalanceD-HF trial of balcinrenone (AZD9977) + dapagliflozin for heart failure in 2025. Discover which therapies are expected to grab the major chronic heart failure market share @ Chronic Heart Failure Market Report Chronic Heart Failure Overview Chronic heart failure is a long-term condition in which the heart's ability to pump blood efficiently is reduced, leading to inadequate circulation of oxygen and nutrients to meet the body's needs. The primary causes of CHF include coronary artery disease, high blood pressure, diabetes, cardiomyopathy, valvular heart disease, and previous heart attacks. Lifestyle factors like obesity, smoking, excessive alcohol consumption, and a sedentary lifestyle can also contribute to its development. The symptoms of CHF vary in severity and may include persistent fatigue, shortness of breath, swelling in the legs, ankles, or abdomen, rapid or irregular heartbeat, and difficulty exercising. Advanced cases can lead to severe fluid retention, wheezing, and an inability to carry out daily activities. Diagnosis typically involves a comprehensive medical history review and a physical examination, followed by tests like an ECG to assess heart rhythm, echocardiography to evaluate heart structure and function, blood tests, chest X-rays, and stress tests. Early diagnosis and management are crucial to improving quality of life and preventing complications. Chronic Heart Failure Epidemiology Segmentation The chronic heart failure epidemiology section provides insights into the historical and current chronic heart failure patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The chronic heart failure market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Diagnosed Prevalent Cases of Heart Failure Gender-specific Cases of Heart Failure Ejection Fraction-specific Cases of Heart Failure New York Heart Association (NYHA) Class-specific Cases of Heart Failure Type-specific Cases of Heart Failure Age-specific Cases of Heart Failure Chronic Heart Failure Treatment Market Current treatments for heart failure primarily rely on angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and diuretics. Additional therapies, such as aldosterone antagonists, amiodarone, antiplatelets, anticoagulants, calcium channel blockers, and nitrates, are also utilized in managing the condition. Most treatment regimens involve a combination of therapies, with beta-blockers being among the most commonly prescribed. Among the approved treatments, Novartis' ENTRESTO has emerged as a leading drug in the congestive heart failure market. Initially slow to gain traction, ENTRESTO has become one of Novartis' key growth drivers, with revenue expected to increase in the coming years. Following its approval for use in patients with preserved ejection fraction, ENTRESTO's market presence has grown significantly. However, ENTRESTO faces growing competition. The entry of new drugs, including SGLT2 inhibitors (such as FARXIGA and JARDIANCE) and VERQUVO, poses a challenge to ENTRESTO's dominance. Additionally, Novartis is set to lose ENTRESTO's exclusivity in the United States in 2025, raising the risk of generic competition. The company is actively engaged in several patent lawsuits to protect its position. SGLT2 inhibitors have also gained a foothold in the CHF market. Although FARXIGA and JARDIANCE are established drugs, they are relatively new in this therapeutic area. The outlook for SGLT2 inhibitors in heart failure is promising, but AstraZeneca and Lilly/Boehringer will have limited time to solidify their positions, as FARXIGA's US patent expires in 2025 and JARDIANCE's in 2028. The recently approved SGLT2 inhibitor sotagliflozin may face challenges in capturing market share from these established treatments. To know more about chronic heart failure treatment guidelines, visit @ Chronic Heart Failure Management Chronic Heart Failure Pipeline Therapies and Key Companies Omecamtiv Mecarbil: Cytokinetics KERENDIA (finerenone): Bayer Tirzepatide (LY3298176): Eli Lilly and Company CardiAMP Cell Therapy: BioCardia Ziltivekimab (NN6018): Novo Nordisk REVASCOR (rexlemestrocel-L): Mesoblast Levosimendan (TNX-103): Tenax Therapeutics Semaglutide: Novo Nordisk Balcinrenone (AZD9977) + dapagliflozin: AstraZeneca Mitiperstat (AZD4831): AstraZeneca Vicadrostat (BI 690517) + Empagliflozin: Boehringer Ingelheim Cimlanod (CXL-1427/BMS-986231): Bristol Myers Squibb Lenrispodun (ITI - 214): Intra-Cellular Therapies CRD-740: Cardurion Pharmaceuticals HU6: Rivus Pharmaceuticals Discover more about chronic heart failure drugs in development @ Chronic Heart Failure Clinical Trials Chronic Heart Failure Market Dynamics The chronic heart failure market dynamics are expected to change in the coming years. An increasing prevalence of cardiovascular diseases, fueled by aging populations and lifestyle-related risk factors such as obesity, hypertension, and diabetes, has significantly raised the demand for effective CHF treatments. Advances in medical technology, including innovative drug therapies, cardiac devices, and regenerative medicine, are expanding treatment options and improving patient outcomes. Growing awareness about heart health and early diagnosis, supported by government and non-government initiatives, is also boosting market expansion. Additionally, the rising focus on personalized medicine and the development of therapies targeting the underlying molecular mechanisms of CHF are creating lucrative opportunities. The increasing healthcare expenditure and the availability of reimbursement policies in developed and emerging economies further bolster the market's growth trajectory. Furthermore, potential therapies are being investigated for the treatment of chronic heart failure, and it is safe to predict that the treatment space will significantly impact the chronic heart failure market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the chronic heart failure market in the 7MM. However several factors may impede the growth of the chronic heart failure market. A key challenge is the underdiagnosis and delayed recognition of CHF due to overlapping symptoms with other conditions and the lack of widespread access to advanced diagnostic tools in many regions. Economic constraints, particularly in low- and middle-income countries, limit patient access to costly therapies, including advanced drugs and devices. Additionally, adherence to treatment regimens remains low due to the complexity of management protocols and the long-term nature of care, leading to suboptimal outcomes. Regulatory hurdles and lengthy approval processes for novel therapies further impede the introduction of innovative treatments. Finally, a limited understanding among general practitioners about newer guidelines and therapies reduces the referral rates to specialists, creating gaps in patient care. Addressing these barriers requires concerted efforts in education, affordability, and healthcare infrastructure. Scope of the Chronic Heart Failure Market Report Therapeutic Assessment: Chronic Heart Failure current marketed and emerging therapies Chronic Heart Failure Market Dynamics: Key Market Forecast Assumptions of Emerging Chronic Heart Failure Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Chronic Heart Failure Market Access and Reimbursement Download the report to understand which factors are driving chronic heart failure market trends @ Chronic Heart Failure Market Trends Table of Contents Related Reports Chronic Heart Failure Epidemiology Forecast Chronic Heart Failure Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the chronic heart failure epidemiology trends. Chronic Heart Failure Pipeline Chronic Heart Failure Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CHF companies, including Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, Ionis Pharmaceuticals, Berlin Cures, CardioCell, Help Therapeutics, Eli Lilly and Company, Chong Kun Dang Pharmaceutical, Antlia Biosciences, Cardiol Therapeutics, among others. Acute Coronary Syndrome Market Acute Coronary Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ACS companies, including Novartis, Boehringer Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra , among others. Acute Coronary Syndrome Pipeline Acute Coronary Syndrome Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute coronary syndrome companies, including Janssen Research & Development, LLC, DalCor Pharmaceuticals, Hyloris Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED